[ad_1]
NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP announces that it has launched an investigation into NRx Pharmaceuticals, Inc. (“NRx” or the “Company”) (NASDAQ:NRXP, NRXPW)) and some of its officials. The class action, filed in the U.S. District Court for the District of Delaware, docket number 22-cv-00066, represents a class consisting of all individuals and entities other than defendants who purchased or Otherwise acquired NRx securities January 1, 2021 and November 4, 2021, both dates inclusive (the “Class Action Period”), seeking to recover damages resulting from Defendant’s violation of the federal securities laws and pursuant to Section 10 Sections (b) and 20(a) seek to remedy the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 10b-5 promulgated thereunder against the Corporation and certain of its senior officers.
If you are a shareholder who purchased or otherwise acquired NRx during a class action, you must ask the court to appoint you as lead plaintiff for the class by March 21, 2022.A copy of the complaint can be obtained at
The full story is available on Benzinga.com
[ad_2]
Source link
